Bevacizumab Pregnancy and Breastfeeding Warnings

Bevacizumab is also known as: Avastin

Bevacizumab Pregnancy Warnings

Angiogenesis is critical to fetal development and the inhibition of angiogenesis following administration of bevacizumab is likely to result in adverse effects on pregnancy. Patients who discontinue bevacizumab should also be counseled concerning the prolonged exposure following discontinuation of therapy (half-life approximately 20 days) and the possible effects on fetal development. The incidence of ovarian failure was higher (34% vs. 2%) in premenopausal women receiving bevacizumab in combination with mFOLFOX chemotherapy as compared to those receiving mFOLFOX chemotherapy alone for adjuvant treatment for colorectal cancer, a use for which bevacizumab is not approved. Inform females of reproductive potential of the risk of ovarian failure prior to starting treatment with bevacizumab.

Bevacizumab has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity. There are no controlled data in human pregnancy. Bevacizumab should only be given during pregnancy when benefits outweigh risks.

Bevacizumab Breastfeeding Warnings

There are no data on the excretion of bevacizumab into human milk. Human IgG1 is secreted into human milk. The potential for absorption and harm to the infant after ingestion is unknown. Women should be advised to discontinue nursing during treatment with bevacizumab and for a prolonged period following therapy with bevacizumab, taking into account that the half-life averages approximately 20 days.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web3)